Liquidia Technologies Inc (LQDA)vsMerck & Company Inc (MRK)
LQDA
Liquidia Technologies Inc
$42.30
+0.05%
HEALTHCARE · Cap: $3.76B
MRK
Merck & Company Inc
$111.38
-0.82%
HEALTHCARE · Cap: $277.36B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 41441% more annual revenue ($65.77B vs $158.32M). MRK leads profitability with a 13.6% profit margin vs -43.5%. MRK earns a higher WallStSmart Score of 50/100 (D+).
LQDA
Hold38
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LQDA.
Margin of Safety
-13.8%
Fair Value
$97.84
Current Price
$111.38
$13.54 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 3055.0% year-over-year
Strong operational efficiency at 21.5%
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Trading at 82.9x book value
ROE of -111.1% — below average capital efficiency
Currently unprofitable
Premium valuation, high expectations priced in
4.9% revenue growth
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : LQDA
The strongest argument for LQDA centers on Revenue Growth, Operating Margin. Revenue growth of 3055.0% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : LQDA
The primary concerns for LQDA are EPS Growth, Price/Book, Return on Equity.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
LQDA profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
LQDA carries more volatility with a beta of 0.42 — expect wider price swings.
LQDA is growing revenue faster at 3055.0% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 38/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Liquidia Technologies Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and markets various products for the unmet needs of patients in the United States. The company is headquartered in Morrisville, North Carolina.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?